The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's (SC) leading academic medical center, MUSC is charged with building basic, translational, clinical, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in SC through transformative research, patient care, prevention, and public policy. To accomplish this mission, HCC leadership built a robust, multidisciplinary center that includes 107 cancer scientists. Innovative, high-impact research is driven by HCC?s four research programs: Cancer Biology, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by five shared research resources: Lipidomics, Flow Cytometry & Cell Sorting, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. During the current project period, the HCC successfully leveraged CCSG funding and its NCI-designated cancer center status to harness, expand and improve the center?s research capabilities to decrease the state?s cancer burden. HCC supported recruitment of 26 new cancer scientists. The annual direct peer-reviewed extramural research funding (excluding training and career development awards) increased to $21.6M, with $10.5M from NCI. HCC boasts the state?s largest clinical trials operation that provides centralized support for conducting the most contemporary cancer trials. During the past year, the HCC recruited 1,266 patients to interventional studies and 254 patients to non-interventional studies. HCC made significant progress in overcoming the challenges inherent in recruiting racial and ethnic minorities to participate in research. In 2017, 33% of research participants were racial or ethnic minorities, with more than half residing in rural communities federally designated as medically underserved. This progress has been maintained for over two decades by progressive, HCC-led outreach, community engagement, and cancer education services. With the charge of training the next generation of diverse and exceptional cancer physicians and scientists, the center developed the state?s only comprehensive cancer education pipeline for learners across the entire education continuum, from high school through early professional career development. The HCC is committed to providing access to the latest research, educational, and clinical advances to all of South Carolina, and has never been better equipped to fulfill its mission. Led by a new center director appointed in 2017, the HCC will implement its 2023 strategic plan to advance scientific discovery, make impactful contributions to the understanding of cancer biology in a diverse population, and translate discoveries into transformative approaches to cancer control, diagnosis, treatment, and public policy.
The Hollings Cancer Center at the Medical University of South Carolina coordinates scientific research to promote interdisciplinary collaborations and translation of cancer research from the bench to the bedside to the community. Through the funding of the P30 Cancer Center Support Grant, the center provides research resources in support of its scientists, with the goal of reducing the cancer burden in South Carolina.
|Graboyes, Evan M; Kompelli, Anvesh R; Neskey, David M et al. (2018) Association of Treatment Delays With Survival for Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg :|
|Bai, Aiping; Bielawska, Alicja; Rahmaniyan, Mehrdad et al. (2018) Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites. Bioorg Med Chem 26:6067-6075|
|Bea, Vivian J; Cunningham, Joan E; Alberg, Anthony J et al. (2018) Alcohol and Tobacco Use in an Ethnically Diverse Sample of Breast Cancer Patients, Including Sea Island African Americans: Implications for Survivorship. Front Oncol 8:392|
|Burris, Jessica L; Rivera-Rivera, Jessica N; Armeson, Kent et al. (2018) Causal attributions and their impact on psychosocial functioning in head and neck cancer patient-caregiver dyads: a preliminary, longitudinal study. Qual Life Res :|
|Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704|
|Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800|
|Jin, Junfei; Lu, Zhongyang; Li, Yanchun et al. (2018) LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. J Leukoc Biol 104:843-853|
|Janakiraman, Harinarayanan; House, Reniqua P; Gangaraju, Vamsi K et al. (2018) The Long (lncRNA) and Short (miRNA) of It: TGF?-Mediated Control of RNA-Binding Proteins and Noncoding RNAs. Mol Cancer Res 16:567-579|
|Joseph, Anne M; Rothman, Alexander J; Almirall, Daniel et al. (2018) Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 197:172-182|
|Rojewski, Alana M; Tanner, Nichole T; Dai, Lin et al. (2018) Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest 154:110-118|
Showing the most recent 10 out of 536 publications